Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HGG-2006 dendritic cell vaccine add-on trial in newly diagnosed glioblastoma
2006-002881-20Phase 2Completed
- Sponsor
- UZ Leuven
- Start
- Jun 2006
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of WT1/hTERT/Survivin-loaded dendritic cell vaccine in glioblastoma (GBM), sponsored by UZ Leuven. Primary endpoint: Progression-free survival at 6 months. Started Jun 2006; status: completed.
02
Drugs
WT1/hTERT/Survivin-loaded dendritic cell vaccine
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2006-002881-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002881-20.